What Continuity Biosciences does

Continuity Biosciences is a clinical-stage biotechnology company developing proprietary precision drug delivery platforms based on iontophoresis and nanofluidic membrane technologies. The company is advancing six therapy-agnostic platform programs targeting pancreatic cancer (Iontophoretic Oncology Platform, IOP), oral cavity cancer (NCI-supported), Type 1 Diabetes (NICHE cell-therapy platform), HIV pre-exposure prophylaxis (nanoDDI long-acting implant), triple-negative breast cancer (NDES drug-eluting seed), and medical aesthetics (precision microneedle cosmetic patch). Preclinically, the company reports 7x higher intratumoral gemcitabine concentrations versus systemic delivery, approximately 98% lower systemic exposure with IOP delivery versus IV chemotherapy, and sustained glycemic control for up to 193 days post-transplantation in NICHE preclinical studies.

The technology portfolio is supported by 80 patents and 135 scientific publications and is anchored by Co-Founder and Chief Technology Advisor Alessandro Grattoni, who chairs the Center for BioNanoengineering at Houston Methodist Hospital. In June 2025 the company acquired Focal Medical, a North Carolina biopharmaceutical firm developing site-specific iontophoresis chemotherapy for pancreatic cancer, transferring its patent estate, scientific know-how, and staff into Continuity's operations. As of mid-2026, Continuity Biosciences had initiated a first-in-human Phase I clinical trial of gemcitabine delivered via IOP (NCT07481383) at WVU Medicine J.W. Ruby Memorial Hospital and University of Michigan Medical Center, with University of Virginia also listed as a trial site.

The company's revenue model is licensing and co-development partnerships with pharmaceutical companies, supplemented by non-dilutive grant and partnership funding (e.g., Breakthrough T1D Industry Discovery and Development Partnership, NCI). It has raised roughly $14.4 million across three disclosed financings between July 2024 and August 2025. Continuity Biosciences is privately held, headquartered in Cary, North Carolina with operational headquarters in Turin, Italy, and operates with 1–10 employees led by Co-Founder and CEO Ramakrishna Venugopalan (former AbbVie executive) and Executive Chair Robert Whitehead.

Name

Continuity Biosciences

Legal name

Continuity Biosciences, LLC

Website

https://continuitybiosciences.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Continuity Biosciences is a clinical-stage biotechnology company developing proprietary iontophoretic and nanofluidic drug delivery platforms targeting pancreatic and oral cancers, Type 1 Diabetes, HIV PrEP, triple-negative breast cancer, and medical aesthetics, monetized via licensing and co-development with pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Drug Delivery Medical Devices

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113), Research and Development in Nanotechnology (541713), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

akta.pro secondary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Precision drug delivery
• Iontophoretic delivery
• Nanofluidic implants
• Combination products
• Implantable therapeutics

Headquarters

HQ city

Bradenton

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Platform Technology Licensing and Development Partnerships: Continuity Biosciences develops proprietary delivery platforms designed to be therapy-agnostic and applicable across multiple therapeutic areas. The company is structured to generate revenue through licensing agreements, co-development partnerships with pharmaceutical companies, and potential future commercialization of its proprietary delivery systems.
2. Biotechnology Investment Funding: The company raised $5 million total in an SEC exempt securities offering, with $2.45 million already sold as of July 2024, focused on biotechnology investments.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Continuity Biosciences is a clinical-stage biotechnology company that develops proprietary precision drug delivery platforms based on iontophoresis and nanofluidic membrane technologies. Its platforms include the Iontophoretic Oncology Platform (IOP), the NICHE cell-therapy combination product, the nanoDDI implant, and the NDES drug-eluting seed, targeting oncology, Type 1 Diabetes, HIV prevention, and medical aesthetics. The company advances these therapy-agnostic delivery systems through clinical trials and plans to monetize them via licensing and co-development partnerships with pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Iontophoretic Oncology Platform (IOP) An implantable iontophoretic system that uses mild electrical current to deliver chemotherapy directly into tumor tissue, maximizing intratumoral drug concentration while minimizing systemic exposure. Indicated initially for pancreatic and oral cavity cancers.
• NICHE Cell-Therapy Platform A subcutaneously implantable combination product designed to house insulin-producing cells within a prevascularized graft chamber while delivering localized immunomodulatory agents from a dedicated drug reservoir, intended to restore insulin production in Type 1 Diabetes without systemic immunosuppression.
• nanoDDI (Nanofluidic Drug Delivery Implant)

Quantifiable outcome

• 7x higher gemcitabine concentrations in pancreatic tissue compared with systemic delivery
• +5 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and major.

• WVU Medicine, University of Virginia, University of MichigancoreStrategic or Co-development Partner · 20 May 2026Clinical trial partnerships with leading U.S. university medical centers including WVU Medicine J.W. Ruby Memorial Hospital, University of Virginia, and University of Michigan Medical Center for Phase I first-in-human clinical trials evaluating gemcitabine delivered via Continuity's proprietary iontophoretic oncology platform for pancreatic cancer treatment.
• Breakthrough T1DcoreStrategic or Co-development Partner · 24 March 2026Strategic collaboration to advance Continuity's NICHE cell-therapy platform toward a planned first-in-human Phase 1/2a clinical study for Type 1 Diabetes treatment. The partnership is supported through Breakthrough T1D's Industry Discovery and Development Partnership (IDDP) program and will fund IND-enabling development activities. The NICHE platform integrates a prevascularized graft chamber for insulin-producing cells with a dedicated drug reservoir for localized immunomodulatory delivery, with the goal of minimizing systemic immunosuppression while improving graft durability.
• Focal MedicalcoreStrategic or Co-development Partner · 4 June 2025Continuity Biosciences acquired Focal Medical, a North Carolina-based biopharmaceutical company specializing in site-specific chemotherapy for solid tumors including pancreatic cancer. The acquisition included Focal Medical's patent estate, iontophoresis technology, scientific know-how, and staff to support clinical development of targeted drug delivery. This acquisition enhanced Continuity's portfolio and leadership in device-targeted therapeutics for solid tumors.
• National Cancer InstitutemajorStrategic or Co-development PartnerThe oral cancer program is supported by the National Cancer Institute (NCI), which provides funding and research support for the iontophoretic drug delivery platform being advanced for oral cavity cancer treatment.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Medtronic: Global medical device leader with an implantable drug delivery franchise (synchroMed, MiniMed insulin pumps) and significant oncology and diabetes adjacencies. Comparable as a large incumbent in implantable and drug delivery devices, though operating across a much broader portfolio than Continuity's focused platform approach.
• Becton, Dickinson and Company (BD): Major medical technology company with extensive drug delivery device portfolio including prefillable syringes, autoinjectors, and advanced delivery systems. Comparable as an established incumbent in injectable drug delivery with global scale and pharma partnerships.

Direct peers

• Insulet Corporation: Developer of the Omnipod insulin delivery system for diabetes management, directly relevant to Continuity's interest in novel subcutaneous delivery for diabetes therapeutics. Comparable as a commercial-stage company addressing insulin/Type 1 Diabetes delivery via wearable/implantable device architectures.
• Vertex Pharmaceuticals: Vertex acquired ViaCyte to advance cell therapy for Type 1 Diabetes (now VX-880/zimislecel program). Direct competitor in the T1D cell therapy space that Continuity's NICHE platform targets, though operating at much larger scale with cell infusion rather than implantable encapsulation.
• Delcath Systems: Developer of the Hepzato Kit for liver-directed chemotherapy delivery, recently FDA-approved. Direct peer in localized/liver-directed chemotherapy delivery for solid tumors, with a similar focus on overcoming systemic toxicity through targeted drug delivery.
• BioDelivery Sciences International: Specialty pharmaceutical company focused on novel drug delivery technologies including buccal film delivery platforms. Comparable as a smaller specialty pharma using proprietary delivery platforms to enhance therapeutic profiles, though in pain rather than oncology.
• PharmaCyte Biotech: Clinical-stage biotechnology company developing cell encapsulation technology for localized cancer chemotherapy delivery (Cell-in-a-Box platform) targeting pancreatic cancer. Direct peer in implantable encapsulation-based localized drug delivery for solid tumors.

Emerging players

• Sorrento Therapeutics: Clinical-stage biopharmaceutical company developing therapies for cancer and pain, with work in localized intratumoral delivery and immuno-oncology. Comparable as an emerging player in novel oncology delivery approaches including intratumoral immunotherapy.
• Aprea Therapeutics: Clinical-stage biopharmaceutical company developing precision oncology therapeutics, including work in pancreatic cancer. Comparable as an emerging player targeting similar high-unmet-need oncology indications with novel therapeutic approaches.

Regional players

• Tandem Diabetes Care: Developer of the t:slim X2 insulin pump for Type 1 Diabetes management. Comparable as a diabetes delivery technology company, though focused on external pumps rather than implantable/cell-based approaches like Continuity's NICHE platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/continuity-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Continuity Biosciences